Centogene: Rises after FDA grants emergency use of COVID-19 test

Crown LiquidationCo NV in liquidatie

02/07/2020 14:13

** U.S.-listed shares of Germany-based diagnostic and pharma
co  CNTG.O  rise 9.2% to $27.49 premarket
    ** U.S. FDA grants emergency use authorization to co's
COVID-19 molecular diagnostic test  urn:newsml:reuters.com:*:nGNX2PSs2Z
    ** Test, that uses swabs from upper respiratory tract, is
intended for use by qualified lab personnel 
    ** In April, CNTG launched swab sampling kit, CentoSwab, to
facilitate detection of SARS-CoV-2, which causes COVID-19 
    ** Stock up ~150% this year, up to last close

 (Reporting By Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))